Margherita Milone

Dr. Margherita Milone

Neurology, Mayo Clinic, Rochester, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
CKCharles D. Kassardjian
Charles D. Kassardjian
VLVanda A. Lennon
Vanda A. Lennon
NANora B. Alfugham
Nora B. Alfugham
MMMichael Mahler
Michael Mahler
MMMargherita Milone
Margherita Milone
Necrotizing autoimmune myopathy (NAM) presents with subacute proximal limb muscle weakness and a high serum creatine kinase (CK) level.1-3 In contrast to idiopathic inflammatory myopathies characterized histopathologically by an inflammatory exudate, biopsied muscle in NAM has prominent fiber necrosis and regeneration with minimal or no inflammation.1,3-5

7 February 2018 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
TLTeerin Liewluck
Teerin Liewluck
MMMargherita Milone
Margherita Milone

1 March 2010 in The Neurologist
Verified
Journal Article
Closed access
MMMargherita Milone
Margherita Milone
RMRami Massie
Rami Massie
Mitochondrial disorders result from primary defects in the mitochondrial DNA (mtDNA) or from defects in nuclear genes which cause disease by affecting the mtDNA. POLG1 is a nuclear gene which encodes for the catalytic subunit of the mtDNA polymerase gamma, essential for mtDNA replication. Less than a decade ago, POLG1 mutations were discovered in patients with progressive external ophthalmoplegia. Since then, it has emerged that POLG1 mutations can result in a spectrum of clinical manifestations, resulting in autosomal recessive or dominant mitochondrial diseases. Here we summarize the common clinical phenotypes associated with POLG1 mutations. Alpers syndrome, progressive external ophthalmoplegia with or without limb myopathy, ataxia-neuropathy syndrome, and epilepsy are frequent clinical manifestations of the POLG1-related disease. Childhood progressive encephalopathy, Parkinsonism, stroke-like events, and isolated exercise intolerance can occur in association with POLG1 mutations. Muscle biopsy can show signs of mitochondrial dysfunction by histologic and biochemical studies or it can be unrevealing. mtDNA analysis of affected tissues can reveal depletion, multiple deletions or point mutations, but it can be occasionally noninformative by routine analysis. : POLG1 mutations result in extremely heterogenous phenotypes which often have overlapping clinical findings, making it difficult to categorize patients into syndromes. The lack of signs of mitochondrial dysfunction in the muscle biopsy does not exclude a POLG1-related disease. Analysis of mtDNA of clinically affected tissues is often informative, but not always. Molecular analysis of POLG1 is essential when POLG1-related disease is suspected. Sodium valproate should be avoided because of the risk of liver failure.

1 May 2017 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MMMargherita Milone
Margherita Milone

21 July 2009 in Neurology
Verified
Journal Article
Closed access
MMMargherita Milone
Margherita Milone
XSX. M. Shen
X. M. Shen
DSD. Selcen
D. Selcen
KOKinji Ohno
Kinji Ohno
JBJ. Brengman
J. Brengman
AEA. G. Engel
A. G. Engel
Pathogenic mutations in rapsyn result in endplate acetylcholine receptor (AChR) deficiency and are a common cause of postsynaptic congenital myasthenic syndromes. Clinical, electrophysiologic, pathologic, and molecular studies were done in 39 patients. In all but one patient, the disease presented in the first 2 years of life. In 9 patients, the myasthenic symptoms included constant or episodic ophthalmoparesis, and 1 patient had a pure limb-girdle phenotype. More than one-half of the patients experienced intermittent exacerbations. Long-term follow-up was available in 25 patients after start of cholinergic therapy: 21 became stable or were improved and 2 of these became asymptomatic; 3 had a progressive course; and 1 died in infancy. In 7 patients who had endplate studies, the average counts of AChR per endplate and the synaptic response to ACh were less reduced than in patients harboring low AChR expressor mutations. Eight patients were homozygous and 23 heterozygous for the common p.N88K mutation. Six mutations, comprising 3 missense mutations, an in-frame deletion, a splice-site mutation, and a nonsense mutation, are novel. Homozygosity for p.N88K was associated with varying grades of severity. No genotype-phenotype correlations were observed except in 8 Near-Eastern patients homozygous for the promoter mutation (c.-38A>G), who had a mild course. All but 1 patient presented early in life and most responded to cholinergic agonists. With early diagnosis and therapy, rapsyn deficiency has a benign course in most patients. There was no consistent phenotype-genotype correlation except for an E-box mutation associated with jaw deformities.

13 October 2011 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
STSha Tang
Sha Tang
EDElliot L. Dimberg
Elliot L. Dimberg
MMMargherita Milone
Margherita Milone
LWLee-Jun C. Wong
Lee-Jun C. Wong